NCT00508625 - A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab | Biotech Hunter

Enrollment

213

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

March 31, 2009

Study Completion Date

November 30, 2011

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

AMG 951 (rhApo2L/TRAIL)

AMG 951 is recombinant human Apo2Ligand/Tumor necrosis factor related apoptosis inducing ligand (rhApo2L/TRAIL) that triggers apoptosis through activation of death receptor 4 (DR4) and death receptor 5 (DR5).

DRUG

Bevacizumab

Bevacizumab is a recombinant humanized version of a murine antibody to vascular endothelial growth factor (VEGF).

DRUG

Carboplatin

Standard platinum based chemotherapy

DRUG

Paclitaxel

Standard taxane chemotherapy